9 research outputs found

    The distribution and density of water mice (Xeromys myoides) in the Maroochy River of Southeast Queensland, Australia

    Get PDF
    The water mouse is a small and vulnerable rodent present in coastal areas of south-west Papua New Guinea, and eastern Queensland and the Northern Territory of Australia. Current knowledge regarding the distribution of the water mouse is incomplete and the loss of one local population has been documented in southeast Queensland, a region where pressures from urban and industrial development are increasing. Water mouse populations have not been studied intensively enough to enable the primary factors responsible for the local decline to be identified. We surveyed the distribution and density of the water mouse along the Maroochy River of southeast Queensland, near the southern extent of the species’ range, to gather baseline data that may prove valuable for detecting any future decline in this population’s size or health. All areas of suitable habitat were surveyed on foot or by kayak or boat over a three-year period. We found 180 water mouse nests, of which ~94% were active. Permanent camera monitoring of one nest and limited supplementary live trapping suggested that up to three individual mice occupied active nests. Water mouse density was estimated to be 0.44 per hectare of suitable habitat along the Maroochy River. Should future monitoring reveal an adverse change in the water mouse population on the Maroochy River, a concerted effort should be made to identify contributing factors and address proximate reasons for the decline

    Recent invasion of European red foxes (Vulpes vulpes) on to Fraser Island (K'gari) and South Stradbroke Island

    No full text
    Invasive predators are globally significant drivers of threatened fauna population decline and extinction, and the early detection of new incursions is critical to the chances of successful predator eradication and fauna conservation. Here, we provide evidence of the recent invasion of European red foxes (Vulpes vulpes) on to two large and internationally significant islands off the southeast coast of Queensland, Australia – Fraser Island (K'gari) and South Stradbroke Island. From camera trap footage collected on Fraser Island since 2009, foxes have now been observed on seven different occasions between 2012 and 2016. Two scats collected on South Stradbroke Island in 2013 and 2014 tested positive for fox DNA (and negative for Canis spp. DNA), with fox presence confirmed by subsequent camera trap footage in 2016. These data confirm the recent incursion of foxes on to these islands and suggest that small populations now exist there. Fraser Island and South Stradbroke Island represent key RAMSAR wetland areas of refuge for populations of multiple threatened fauna that have never been previously been exposed to foxes. Fox impacts on these fauna can only be expected to increase without management intervention to eradicate them before they become widespread

    The distribution and density of water mice (Xeromys myoides) in the Maroochy River of southeast Queensland, Australia

    No full text
    The water mouse is a small and vulnerable rodent present in coastal areas of south-west Papua New Guinea, and eastern Queensland and the Northern Territory of Australia. Current knowledge regarding the distribution of the water mouse is incomplete and the loss of one local population has been documented in southeast Queensland, a region where pressures from urban and industrial development are increasing. Water mouse populations have not been studied intensively enough to enable the primary factors responsible for the local decline to be identified. We surveyed the distribution and density of the water mouse along the Maroochy River of southeast Queensland, near the southern extent of the species’ range, to gather baseline data that may prove valuable for detecting any future decline in this population’s size or health. All areas of suitable habitat were surveyed on foot or by kayak or boat over a three-year period. We found 180 water mouse nests, of which ~94% were active. Permanent camera monitoring of one nest and limited supplementary live trapping suggested that up to three individual mice occupied active nests. Water mouse density was estimated to be 0.44 per hectare of suitable habitat along the Maroochy River. Should future monitoring reveal an adverse change in the water mouse population on the Maroochy River, a concerted effort should be made to identify contributing factors and address proximate reasons for the decline

    The density of active and inactive water mouse nests (top) and water mouse individuals (assuming an occupancy rate of two mice per nest; bottom) in suitable habitat across all survey sectors along the lower Maroochy River.

    No full text
    <p>The density of active and inactive water mouse nests (top) and water mouse individuals (assuming an occupancy rate of two mice per nest; bottom) in suitable habitat across all survey sectors along the lower Maroochy River.</p

    Two water mice maintaining a mound-style nest in a mangrove vegetation community of Sector 3 of the Maroochy River system, 8<sup>th</sup> March 2012 (Photo: Janina Kaluza).

    No full text
    <p>Two water mice maintaining a mound-style nest in a mangrove vegetation community of Sector 3 of the Maroochy River system, 8<sup>th</sup> March 2012 (Photo: Janina Kaluza).</p

    Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA).

    Get PDF
    status: publishe

    Empagliflozin in Patients with Chronic Kidney Disease

    No full text
    Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to &lt; 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of &amp; GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P &lt; 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo
    corecore